Characteristics of the patients and comparison with those included in the CETLAM-99 protocol and not evaluable for the study
. | Included in this study . | Not included . | P . |
|---|---|---|---|
| No. patients | 110 | 72 | |
| Age, median (range), y | 44 (16-60) | 45 (18-60) | .7 |
| Older than 50 y (%) | 38 (34) | 30 (42) | |
| Sex, no. (%) | |||
| Male | 66 (60) | 40 (56) | .6 |
| Female | 44 (40) | 32 (44) | |
| Leukocyte count, × 109/L, median (range) | 30 (0.8-410) | 14 (0.8-410) | .1 |
| FAB classification, no. (%) | 0.8 | ||
| M0 | 8 (7) | 2 (3) | |
| M1 | 25 (23) | 17 (23) | |
| M2 | 22 (20) | 15 (21) | |
| M4 | 15 (13) | 15 (21) | |
| M5 | 31 (28) | 16 (22) | |
| M6 | 2 (2) | 2 (3) | |
| AML and dysplasia | 4 (4) | 3 (4) | |
| Not classifiable | 3 (3) | 2 (3) | |
| Cytogenetics, no. (%) | .5 | ||
| Normal, at least 20 metaphases | 70 (64) | 46 (64) | |
| Karyotype complex, fewer than 5 abnormalities | 1 (1) | 1 (1) | |
| +8 | 5 (4) | 3 (4) | |
| 11q23 | 10 (9) | 2 (3) | |
| Other abnormalities | 24 (22) | 20 (28) | |
| FLT3, no. performed (%) | 106 | 34 | .8 |
| Germinal | 71 (67) | 24 (71) | |
| Internal tandem duplication | 35 (33) | 10 (29) | |
| FLT3-D835, no. performed (%) | 107 | 36 | .999 |
| Germinal | 99 (92) | 34 (94) | |
| Mutated | 8 (8) | 2 (6) | |
| MLL, no. (%) | 95/110 | 37/72 | .999 |
| Germinal | 79 (72) | 29 (85) | |
| Rearranged | 16 (28) | 5 (15) | |
| Induction response, no. (%) | .6 | ||
| Complete remission | 86 (78) | 53 (76) | |
| Refractoriness | 11 (10) | 10 (14) | |
| Death | 13 (12) | 7 (10) | |
| Courses induction to CR, no. (%) | .8 | ||
| 1 course | 71 (83) | 43 (81) | |
| 2 courses | 15 (17) | 10 (19) | |
| Stem-cell transplantation | .2 | ||
| Autologous | 43 (68) | 29 (64) | |
| Allo-TPH Allogeneic | 20 (32) | 16 (36) | |
| Overall survival at 2 y, % | 47 | 42 | .8 |
| Probability of relapse at 2 y, % | 53 | 57 | .2 |
. | Included in this study . | Not included . | P . |
|---|---|---|---|
| No. patients | 110 | 72 | |
| Age, median (range), y | 44 (16-60) | 45 (18-60) | .7 |
| Older than 50 y (%) | 38 (34) | 30 (42) | |
| Sex, no. (%) | |||
| Male | 66 (60) | 40 (56) | .6 |
| Female | 44 (40) | 32 (44) | |
| Leukocyte count, × 109/L, median (range) | 30 (0.8-410) | 14 (0.8-410) | .1 |
| FAB classification, no. (%) | 0.8 | ||
| M0 | 8 (7) | 2 (3) | |
| M1 | 25 (23) | 17 (23) | |
| M2 | 22 (20) | 15 (21) | |
| M4 | 15 (13) | 15 (21) | |
| M5 | 31 (28) | 16 (22) | |
| M6 | 2 (2) | 2 (3) | |
| AML and dysplasia | 4 (4) | 3 (4) | |
| Not classifiable | 3 (3) | 2 (3) | |
| Cytogenetics, no. (%) | .5 | ||
| Normal, at least 20 metaphases | 70 (64) | 46 (64) | |
| Karyotype complex, fewer than 5 abnormalities | 1 (1) | 1 (1) | |
| +8 | 5 (4) | 3 (4) | |
| 11q23 | 10 (9) | 2 (3) | |
| Other abnormalities | 24 (22) | 20 (28) | |
| FLT3, no. performed (%) | 106 | 34 | .8 |
| Germinal | 71 (67) | 24 (71) | |
| Internal tandem duplication | 35 (33) | 10 (29) | |
| FLT3-D835, no. performed (%) | 107 | 36 | .999 |
| Germinal | 99 (92) | 34 (94) | |
| Mutated | 8 (8) | 2 (6) | |
| MLL, no. (%) | 95/110 | 37/72 | .999 |
| Germinal | 79 (72) | 29 (85) | |
| Rearranged | 16 (28) | 5 (15) | |
| Induction response, no. (%) | .6 | ||
| Complete remission | 86 (78) | 53 (76) | |
| Refractoriness | 11 (10) | 10 (14) | |
| Death | 13 (12) | 7 (10) | |
| Courses induction to CR, no. (%) | .8 | ||
| 1 course | 71 (83) | 43 (81) | |
| 2 courses | 15 (17) | 10 (19) | |
| Stem-cell transplantation | .2 | ||
| Autologous | 43 (68) | 29 (64) | |
| Allo-TPH Allogeneic | 20 (32) | 16 (36) | |
| Overall survival at 2 y, % | 47 | 42 | .8 |
| Probability of relapse at 2 y, % | 53 | 57 | .2 |
CR indicates complete remission.